Anti-Lassa Virus, Nucleoprotein (Clone LV-0025)

Anti-Lassa Virus, Nucleoprotein (Clone LV-0025)

Product No.: L316

- -
- -
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Lassa, LASV, Lassa Virus
Mouse IgG1 κ
Lateral Flow

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactivity Species
Lassa Virus
Host Species
Product Concentration
≥1.0 mg/ml
Formulated in 0.015 M potassium phosphate buffere, 0.85% NaCl, pH 7.2 and contains 0.05% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Product Preparation
This monoclonal antibody is purified by ion exchange chromatography.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
Lateral Flow
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Anti-Lassa Virus (Clone LV-0025) is specific for the Nucleoprotein of Lassa Virus.
Lassa virus, a member of the Arenaviridae family, is a zoonotic pathogen primarily found in West Africa, particularly in regions such as Nigeria, Sierra Leone, and Liberia. The virus is transmitted to humans primarily through contact with rodent excreta or consumption of contaminated food. Lassa fever, the disease caused by the virus, manifests with flu-like symptoms initially but can progress to severe complications including hemorrhage and organ failure. Timely diagnosis is crucial for effective management, typically involving laboratory tests such as enzyme-linked immunosorbent assay (ELISA) or reverse transcriptase-polymerase chain reaction (RT-PCR) to detect viral antigens or genetic material in blood or tissue samples. Early detection allows for prompt treatment with antiviral medications and supportive care, significantly improving patient outcomes and reducing mortality rates associated with Lassa fever.

Antigen Details

Research Area
Category A Pathogens
Infectious Disease
Matched Pair
IVD Raw Material

References & Citations

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB). Link
Indirect Elisa Protocol
Lateral Flow
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.